Test offers EoE patients a simple, clinically proven method to control their disease. “…Beyond thrilled to use this at Phoenix Children’s Hospital…” – Dr. Schroeder, Medical Director, Eosinophilic Disease Clinic, Phoenix Children’s Hospital

AURORA, Colo. – October 24, 2022 – (Newswire.com)

Clinicians with the Gastrointestinal Eosinophilic Disease Program at the Digestive Health Institute, Children’s Hospital of Colorado, performed the Esophageal String Test^® (EST) on a patient in early September. The test will be offered regularly at the hospital.

The EST was also performed on patients in the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children’s Hospital. 

“I am now beyond thrilled to use this new esophageal surveillance technique at Phoenix Children’s and for my patients with eosinophilic gastrointestinal disorders. The EST is a game-changer for my patients who are looking for a less invasive and less expensive way to screen their disease activity,” said Dr. Shauna Schroeder, Medical Director for the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children’s Hospital. She further stated “Having trained in Denver, I had experience using the EST as a research tool in patients with eosinophilic esophagitis. I am now able to more granularly adjust medications and diets improving the care of my patients with eosinophilic esophagitis.”

The Esophageal String Test^® utilizes a simple collection device, the EnteroTracker^®, to collect upper gastrointestinal samples from adults and children.  The samples are sent to an independent reference lab for analysis of disease activity. Several other clinics around the country are planning to offer the test soon.

About EnteroTrack 

EnteroTrack, an early-stage company, develops simple-to-use, minimally invasive technologies to sample gastrointestinal (GI) mucosal content that can be assayed for various biomarkers of disease. The company’s platform technology, the EnteroTracker^® is initially being used to support clinical monitoring of Eosinophilic Esophagitis in adults and children without need for sedation, advanced training, or complex procedures. Clinical studies evaluating the utility of the EnteroTracker^® for additional applications including Esophageal Adenocarcinoma, Barrett’s Esophagus, GERD, GI microbiome, food allergy testing, and others are currently underway.

Contact Information:

Robin Shandas

CEO, Media and Investor Inquiries

[email protected]

Brookelynn Stillwell

General Inquiries

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the US

Gb Sciences’ anxiety formulations were previously identified using the company’s AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.

GB Sciences

LAS VEGAS – October 24, 2022 – (Newswire.com)

Gb Sciences, Inc. (“GbS”; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at the National Research Council of Canada (NRC). GbS’ proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC is testing GbS’ proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates. These are the company’s first non-cannabis formulations to advance in preclinical studies.

“We have achieved an important milestone in the development of our novel, kava-inspired anxiety formulations. Not only did some of our formulations achieve statistical significance in the animal model, but these minimum essential mixtures also demonstrated synergy by significantly outperforming the individual active ingredients within our minimum essential mixture formulations,” said Dr. Andrea Small-Howard, Gb Sciences’ President and Chief Science Officer. “This preclinical data also confirms that our PhAROS™ platform was capable of yielding concrete, potentially effective, plant-inspired combination drugs.”

For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS™ platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS™ identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines.

The PhAROS^TM platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS™ allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS™ represents a breakthrough combination of data sciences and traditional plant-based medicines. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com. 

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Media Contact

Alexis Quintal

[email protected]

Contact Information:

Madeleine Moench

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

First joint research project between Sanofi and the BioMed X Institute, co-creation of a next-generation virtual patient engine for clinical translation of drug candidates

…

The minimally invasive procedure is a groundbreaking innovation that will help millions of men with BPH for years to come.

Dr. Akinwande This is …

Dr. Robert Masson Performs the First Reconstructive Surgeries Using a Mixed Reality Operating Room Setup and Logistics Platform

Live Surgery Holo…

The healthcare exchange enables nearly 200 million people to share their medical records with caregivers, plans, providers and other organizations.

Mpowered Health launches xChange
xChange is the Nation’s first consumer mediated health data exchange platform

LOS ALTOS, Calif. – October 20, 2022 – (Newswire.com)

Mpowered Health, a consumer healthcare marketplace, today announced that it successfully launched its xChange, the nation’s first consumer mediated healthcare data exchange. 

The exchange enables health plans, health systems and other healthcare organizations to request and obtain medical records from consumers with their consent. Consumers can now conveniently share records with family members and caregivers in addition to healthcare organizations they receive care from.

“There are over 100 million individuals in Medicare and Medicaid, who are vulnerable and in need of caregiver support. The xChange makes it easy for such consumers to share important information about their health with the people and the organizations that support them,” says Nandini Devi, Founder & CEO of Mpowered Health. “Consumers can control at a granular level who sees what information. This offering is the lynchpin of our vision to empower consumers to take control of their healthcare experience while enabling healthcare organizations to serve their consumers more effectively.”   

Consumers can connect to over 600 healthcare organizations such as health systems, medicare advantage & medicaid plans across the country including national payers, blues and regional plans. The Mpowered Health App enables nearly 200 million people across the country to access their medical records, coverage & explanation of benefits information from all these plans and health systems. In addition, the platform delivers a personalized shopping experience for consumers seeking to enroll in medicare and exchange health plans. Mpowered Health is the first healthcare platform in the United States to offer consumers such a convenience at scale.

Founded in 2019, Mpowered Health is a rapidly growing healthcare marketplace that provides a convenient platform for healthcare organizations to acquire, engage and retain consumers, while giving consumers a voice, the transparency, the choice, the access and the convenience they need to manage their own and their family’s health care.

Mpowered Health was featured in the Inc. Magazine and CIO Today in 2022 and as one of the Top Healthcare Interoperability Solution Providers by Healthcare TechOutlook.

About Mpowered Health

Mpowered Health is a consumer-driven healthcare technology company committed to creating a better healthcare experience for consumers and healthcare enterprises. The California-based company empowers consumers to take charge of their healthcare by providing mobile-led solutions that improve transparency, choice, access and convenience. The company, in recognizing that consumer empowerment cannot be a zero-sum game, provides enterprise solutions in compliance, consumer acquisition & engagement to enable healthcare organizations to serve their consumers more effectively and achieve their organizational goals.
 

For more information, visit us at www.mpoweredhealth.com

Media Contact: [email protected]

Contact Information:

Mpowered Health

Press

[email protected]

9740335480

Press Release Service
by
Newswire.com

Original Source:

Mpowered Health Launches xChange, the Nation’s First Consumer Mediated Healthcare Data Exchange

South Beach Detox is offering an executive-level treatment experience to business professionals.

South Beach Detox South Beach Detox
…

Collaboration will accelerate and streamline gastroenterology (GI) clinical trials with an end-to-end platform for patient recruitment, enrollment, and management

…

RBMA Executive Director Bob Still decries Medicare cuts that would ‘damage the health of the American people’

RPAN Logo
RPAN Logo

WASHINGTON – October 20, 2022 – (Newswire.com)

A new study of current or eligible Medicare recipients conducted on behalf of the Radiology Patient Action Network shows that nearly half of women indicate that they have not received a mammogram in the last three years. Conducting and released during Breast Cancer Awareness Month, the study also found that 80 percent of Americans are concerned with proposed cuts to Medicare, and 90 percent of Americans view maintaining Medicare coverage as important.

“As policymakers continue to propose cuts to Medicare, it is clear any new cuts would worsen health inequities and damage the health of the American people,” said Bob Still, Executive Director of the RBMA. “At a time when patients are already having difficulty receiving the care they need — like mammography screenings proven to detect and prevent breast cancer — members of Congress should take note of these findings and protect Medicare.”

Dr. Kellie Schenk, a board-certified diagnostic radiologist with EPIC Imaging, PC, in Oregon and Imaging for a Cause participant, underscored the severity of the survey’s mammography findings. “Breast cancer is the most commonly diagnosed cancer among women and, if not caught and treated early, can be disfiguring and deadly. We recommend average-risk women receive mammography screenings every year beginning at age 40 and high-risk women talk to their doctor about screenings prior to 40 to increase the chances of early detection, which not only saves lives but makes treatment much easier and less disruptive for patients and their families. It is alarming that nearly half of Medicare-aged women haven’t received their annual mammogram given the benefits of screening in this age group, and we encourage them to get one scheduled as soon as possible. It is clear that further cuts to Medicare providers and vital screening services would only exacerbate this issue by limiting appointments and compromising quality of care.”

In addition to survey respondents’ concern for Medicare cuts and lack of mammography screenings, 1 in 4 current patients reported having difficulty scheduling doctors’ appointments due to delays or rescheduling. Almost half of all respondents said they would be less likely to support a member of Congress if they advocate for cuts.

The survey was conducted Sept. 25 through Sept. 27, 2022. The national survey sample consists of 1,632 Americans either enrolled in Medicare or Medicare-eligible. Margin of Error is +/-2.5% with a 95% level of confidence. The study was jointly sponsored by the Medical Imaging and Technology Alliance (MITA), Imaging for a Cause, and the Radiology Business Management Association (RBMA) and conducted by the Remington Research Group.

About Imaging for a Cause

Imaging for a Cause Foundation (ICF) is a 501(c)(3) nonprofit foundation that coordinates communication between imaging centers and Federally Qualified Community Health Centers. It has a decade-long history of fostering charitable care for thousands of patients, from Virginia to Minnesota to Washington State.

About MITA

The Medical Imaging & Technology Alliance (MITA), a division of NEMA, is the collective voice of medical imaging equipment manufacturers, innovators, and product developers. It represents companies whose sales comprise more than 90 percent of the global market for advanced medical imaging technology. For more information, visit www.medicalimaging.org. 

About RBMA

The Radiology Business Management Association (RBMA) is an industry-leading organization comprised of more than 2,100 professionals who focus on the business of radiology. RBMA members support diagnostic imaging, interventional radiology and radiation oncology providers in the full spectrum of practice settings. RBMA connects members nationwide to valuable information, education, and practice-related resources and serves as an authoritative industry voice on behalf of shared member interests.

Contact Information:

Will Sweet

RBMA

[email protected]

Press Release Service
by
Newswire.com

Original Source:

RBMA’s Radiology Patient Action Network Study Shows Nearly Half of Women Not Receiving Recommended Mammograms

Talkiatry’s implementation of Cedar Pay brings a consumer-focused payment experience to a national patient base

NEW YORK – October 20, 2022 – (Newswire.com)

Talkiatry, a leading provider of high-quality, in-network psychiatric care and one of the largest employers of psychiatrists in the United States, announced today that it has partnered with Cedar, an enterprise healthcare engagement platform that improves the end-to-end consumer financial journey, to enhance the online billing experience for its rapidly expanding patient base. 

Launched in 2020, Talkiatry is increasing the accessibility and affordability of high-quality psychiatric care. In network with over 60 major insurance plans, Talkiatry also conducts virtual visits that make it easy for patients to be seen. Talkiatry’s practice employs hundreds of psychiatrists from diverse backgrounds across a range of specialties—from child and adolescent to adult to geriatric—and uses proprietary technology to personalize care and improve outcomes in previously unachievable ways. 

“In psychiatry, billing has long been a challenge for patients,” said Robert Krayn, Talkiatry’s co-founder and CEO. “It’s opaque and complex, and 45% of psychiatrists don’t even accept insurance. We’re changing that. We want our patients to focus on their health, not on trying to decipher confusing statements, and Cedar is an important part of how we use technology to improve the patient experience.”

Cedar Pay, Cedar’s post-visit patient engagement and payment platform, delivers a more streamlined patient financial journey and eases the consumer burden of paying for healthcare. Through Cedar Pay, Talkiatry will be able to empower their national patient base to better manage their healthcare bills through consumer-friendly statements, optimized outreach and flexible payment options. 

“It is often difficult for Americans to access mental health treatment, due to factors like cost of care and lack of in-network providers,” said Florian Otto, Cedar’s co-founder and CEO. “At Cedar, our mission is simple: empower people to easily and affordably pursue the care they need, and we are looking forward to partnering with our first psychiatry provider, Talkiatry, as they enhance their digital strategy to meet patients where they are. And, with a simplified payments experience, their psychiatry providers will be able to focus on providing the best quality care.” 

Cedar Pay is now live and available for Talkiatry’s patients. 

About Talkiatry
Talkiatry is a national mental health practice that provides in-network psychiatry and therapy. They were co-founded by a patient and a triple-board-certified psychiatrist to solve the problems both groups face in accessing and providing the highest quality mental healthcare. 60% of adults in the U.S. with a diagnosable mental illness go untreated every year because care is inaccessible, while 45% of clinicians are out of network with insurers because reimbursement rates are low and paperwork is unduly burdensome. With innovative technology and a human-centered philosophy, Talkiatry provides patients with the care they need—and allows psychiatrists to focus on why they got into medicine. Learn more at www.talkiatry.com and follow us on Instagram, Facebook, and LinkedIn.

About Cedar
Cedar is committed to improving the healthcare billing experience for all. With an innovative platform that connects providers and payers, Cedar empowers healthcare consumers with a personalized journey—all powered by data science and interactive design. For Cedar clients, this leads to increased payments, more efficient operations and greater consumer loyalty. To learn more about why leading U.S. healthcare organizations trust Cedar to manage the end-to-end payments experience from pre-registration to post-visit billing, visit www.cedar.com and join us on LinkedIn, Twitter, Facebook and YouTube.

Contact Information:

Jenny Fiegoli

Cedar

[email protected]

Hirsch Leatherwood

Talkiatry

[email protected]

Press Release Service
by
Newswire.com

Original Source:

One of America’s Largest Employers of Psychiatrists, Talkiatry, Partners With Cedar to Enhance Patients’ Financial Experience